

## REFERENCES

1. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D: A: D): a multicohort collaboration. *Lancet*. 2014;384(9939):241-248.
2. Morlat P, Roussillon C, Henard S, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. *AIDS*. 2014;28(8):1181-1191.
3. Lang S, Boccara F, Mary-Krause M, Cohen A. Epidemiology of coronary heart disease in HIV-infected versus uninfected individuals in developed countries. *Arch Cardiovasc Dis* 2015;108(3):206-215.
4. Feinstein MJ, Bahiru E, Achenbach C, et al. Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013. *Am J Cardiol*. 2016;117(2):214-220.
5. Islam F, Wu J, Jansson J, Wilson D. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. *HIV Med*. 2012;13(8):453-468.
6. Triant VA, Perez J, Regan S, et al. Cardiovascular risk prediction functions underestimate risk in HIV infection. *Circulation*. 2018;137(21):2203-2214.
7. De Socio GV, Ricci E, Parruti G, et al. Statins and aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study. *Infection*. 2016;44(5):589-597.
8. Suchindran S, Regan S, Meigs JB, et al. Aspirin use for primary and secondary prevention in human immunodeficiency virus (HIV)-infected and HIV-uninfected patients. Paper presented at: Open forum infectious diseases 2014.
9. Burkholder G, Zhao H, Drozd D, et al. P168 Statin use among HIV-infected adults by cardiovascular disease risk status. *Eur. Heart J*. 2017;38(suppl\_1).
10. Richardson KK, Bokhour B, McInnes DK, et al. Racial disparities in HIV care extend to common comorbidities: implications for implementation of interventions to reducedisparities in HIV care. *J Natl Med Assoc*. 2016;108(4):201-210 e203.
11. Liew SM, Lee WK, Khoo EM, et al. Can doctors and patients correctly estimate cardiovascular risk? A cross-sectional study in primary care. *BMJ Open*. 2018;8(2):e017711.
12. Pignone M, Phillips CJ, Elasy TA, Fernandez A. Physicians' ability to predict the risk of coronary heart disease. *BMC Health Serv. Res*. 2003;3(1):13.
13. Lloyd-Jones DM, Braun LT, Ndumele CE, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology. *J Am Coll Cardiol*. 2018.
14. Sheridan SL, Crespo E. Does the routine use of global coronary heart disease risk scores translate into clinical benefits or harms? A systematic review of the literature. *BMC Health Serv. Res*. 2008;8:60.

15. Martin SS, Sperling LS, Blaha MJ, et al. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines. *J. Am. Coll. Cardiol.* 2015;65(13):1361-1368.
16. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J. Am. Coll. Cardiol.* 2018;71(19):e127-e248.
17. Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J. Am. Coll. Cardiol.* 2018.
18. Lloyd-Jones DM, Huffman MD, Karmali KN, et al. Estimating longitudinal risks and benefits from cardiovascular preventive therapies among medicare patients: The Million Hearts longitudinal ASCVD risk assessment tool: a special report from the American Heart Association and American College of Cardiology. *Circulation.* 2017;135(13):e793-e813.
19. ASCVD Risk Estimator Plus. <https://www.acc.org/tools-and-practice-support/mobile-resources/features/2013-prevention-guidelines-ascvd-risk-estimator>. Published 2019. Accessed January 6, 2019.
20. Agency for Healthcare Research and Quality. *Strategy 6I: Shared Decision-making*. <http://www.ahrq.gov/cahps/quality-improvement/improvement-guide/6-strategies-for-improving/communication/strategy6i-shared-decisionmaking.html>. Published 2017. Accessed January 6, 2019.